Background: Schizophrenia is associated with significant economic burden. In Brazil, antipsychotics drugs, outpatient and hospital services are provided by the Brazilian National Health System for patients with schizophrenia. However, there are few studies that capture the cost of managing these patients within the Brazilian NHS. This is important to appraise different management approaches within universal healthcare systems. Objective: Describe the costs associated with the treatment of schizophrenia in adults receiving atypical antipsychotics in Brazil from 2000 to 2010 through real world data. Methods: We integrated three national databases for adult patients with schizophrenia receiving one or more atypical antipsychotics. Only direct ...
Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments...
Background: Cost-of-illness (COI) studies provide useful information on the economic burden that sch...
AbstractObjectiveCompare annual health-care costs and resource utilization associated with olanzapin...
Background: Schizophrenia is associated with significant economic burden. In Brazil, antipsychotics ...
BACKGROUND: Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic ...
IntroductionGuidelines for the treatment of psychoses recommend antipsychotic monotherapy. However, ...
Guidelines for the treatment of psychoses recommend antipsychotic monotherapy. However, the rate of ...
Aims: Significant cost is associated with schizophrenia and relapses are one significant cost elemen...
Guidelines for the treatment of psychoses recommend antipsychotic monotherapy. However, the rate of ...
Abstract. Schizophrenia is a chronic disease that requires relatively high treatment costs [1]. Seve...
OBJECTIVE: To estimate the direct costs of schizophrenia for the public sector. METHODS: A study was...
Obiective: To evaluate the direct medical cost of atypical antipsychotic therapy for schizophrenia a...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the antipsychotic maintenance the...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the maintenance therapy with anti...
Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Introduct...
Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments...
Background: Cost-of-illness (COI) studies provide useful information on the economic burden that sch...
AbstractObjectiveCompare annual health-care costs and resource utilization associated with olanzapin...
Background: Schizophrenia is associated with significant economic burden. In Brazil, antipsychotics ...
BACKGROUND: Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic ...
IntroductionGuidelines for the treatment of psychoses recommend antipsychotic monotherapy. However, ...
Guidelines for the treatment of psychoses recommend antipsychotic monotherapy. However, the rate of ...
Aims: Significant cost is associated with schizophrenia and relapses are one significant cost elemen...
Guidelines for the treatment of psychoses recommend antipsychotic monotherapy. However, the rate of ...
Abstract. Schizophrenia is a chronic disease that requires relatively high treatment costs [1]. Seve...
OBJECTIVE: To estimate the direct costs of schizophrenia for the public sector. METHODS: A study was...
Obiective: To evaluate the direct medical cost of atypical antipsychotic therapy for schizophrenia a...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the antipsychotic maintenance the...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the maintenance therapy with anti...
Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Introduct...
Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments...
Background: Cost-of-illness (COI) studies provide useful information on the economic burden that sch...
AbstractObjectiveCompare annual health-care costs and resource utilization associated with olanzapin...